Among these, the panel allows the epigenetic scanning of poorly investigated CpGs located at the intragenic exon 3 island of the KEAP1 gene, that were linked to KRAS mutant status in NSCLC patients (29) and at the SPARC gene promoter, which has been proposed as an interesting prognostic biomarker in NSCLC with useful application in the squamous early-stage group (40). Here, KRAS is linked to non-small cell lung carcinoma.